Magnesium glycinate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Magnesium glycinate
- Accession Number
- DB11189
- Description
Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Magnesium glycinate (DB11189)
- Weight
- Average: 172.423
Monoisotopic: 172.03344845 - Chemical Formula
- C4H8MgN2O4
- Synonyms
- Not Available
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium glycinate. Aclidinium The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Alloin. Almasilate The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Almasilate. Aluminium phosphate The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Aluminium phosphate. Aluminum hydroxide The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Aluminum hydroxide. Amantadine The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Magnesium glycinate. Amiodarone The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Amiodarone. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Take with or without food. Taking magnesium supplements with food may reduce the risk of diarrhea.
Products
- Active Moieties
Name Kind UNII CAS InChI Key Magnesium cation ionic T6V3LHY838 22537-22-0 JLVVSXFLKOJNIY-UHFFFAOYSA-N - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Puralor Magnesium glycinate (1 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine (5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine (2.5 mg/1) + Acetylcysteine amide (5 mg/1) + Ascorbic acid (25 mg/1) + Cholecalciferol (100 [iU]/1) + Citric acid (1.6 mg/1) + Cobamamide (2 mg/1) + Egg phospholipids (42.5 mg/1) + Folic acid (42.5 mg/1) + Gastric intrinsic factor (2.5 mg/1) + Magnesium L-threonate (2.5 mg/1) + Leucovorin (3 mg/1) + Levomefolic acid (0.4 mg/1) + Niacin (0.5 mg/1) + Pantethine (2.5 mg/1) + Papain (20 mg/1) + Riboflavin (0.5 mg/1) + Sodium citrate (0.8 mg/1) + Thiamine chloride (0.5 mg/1) Tablet, chewable Oral Centurion Labs 2014-01-01 2017-09-20 US 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acids
- Alternative Parents
- Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic zwitterions / Organic salts / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- IFN18A4Y6B
- CAS number
- 14783-68-7
- InChI Key
- AACACXATQSKRQG-UHFFFAOYSA-L
- InChI
- InChI=1S/2C2H5NO2.Mg/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2
- IUPAC Name
- magnesium(2+) ion bis(2-aminoacetate)
- SMILES
- [Mg++].NCC([O-])=O.NCC([O-])=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 84645
- PubChem Substance
- 347827939
- ChemSpider
- 76358
- 476818
- Wikipedia
- Magnesium_glycinate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, chewable Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 136.0 mg/mL ALOGPS logP -1.5 ALOGPS logP -3.4 ChemAxon logS -0.1 ALOGPS pKa (Strongest Acidic) 2.31 ChemAxon pKa (Strongest Basic) 9.24 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 66.15 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 26.84 m3·mol-1 ChemAxon Polarizability 6.25 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on December 03, 2015 09:51 / Updated on June 12, 2020 10:53